Percutaneous coronary interventions and statin therapy;Possibilità di prevenzione con statine delle complicanze degli interventi coronarici percutanei

Recenti Progressi in Medicina

Volumn 103, Issue 1, 2012, Pages 5-10

  Mega, Simona ^a   Nusca, Annunziata ^a   Patti, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Acute coronary syndrome; Chronic angina; Myocardial infarction; Percutaneous coronary intervention; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; CELL FUNCTION; CONTRAST INDUCED NEPHROPATHY; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIUM CELL; HEART INFARCTION; HUMAN; INFLAMMATION; PERCUTANEOUS CORONARY INTERVENTION; PERIPROCEDURAL MYOCARDIAL INFARCTION; REVIEW; THROMBOSIS; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ANGIOPLASTY, BALLOON, CORONARY; CONTRAST MEDIA; CORONARY ARTERY DISEASE; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856771499     PISSN: 00341193     EISSN: 20381840     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine-kinase MB fraction after percutaneous coronary interventions. Circulation 1996; 94: 1528-36. (Pubitemid 26320254)
2. Brener SJ, Ellis SG, Schneider J, Topol EJ. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J 2002; 23: 869-76. (Pubitemid 34717422)
3. Heusch G, Kleinbongard P, Böse D, et al. Coronary microembolization: from bedside to bench and back to bedside. Circulation 2009; 120: 1822-36.
4. Cavallini C, Verdecchia P, Savonitto S, et al., on behalf of the Italian Atherosclerosis, Thrombosis and Vascular Biology and Society for Invasive Cardiology (GISE) Investigators. Prognostic value of isolated troponin I Elevation after percutaneous coronary intervention. Circ Cardiovasc Interv 2010; 3: 431-5.
5. Ioannidis JPA, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase- MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003; 42: 1406-11. (Pubitemid 37267281)
6. Dibra A, Mehilli J, Braun S, et al. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am Heart J 2005; 150: 344-50. (Pubitemid 41116262)
7. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schächinger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001; 37: 839-46. (Pubitemid 32202453)
8. Kurz DJ, Naegeli B, Bertel O. A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of post-procedural chest pain and minor myocardial necrosis after elective coronary stenting. Am Heart J 2000; 139: 35-43. (Pubitemid 30043622)
9. Wang FW, Osman A, Otero J, et al. Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation 2003; 107: 2914-9. (Pubitemid 36736632)
10. The EPISTENT Investigators. Randomised placebocontrolled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92.
11. Desmet WJ, Dens J, Coussement P, Van de Werf F. Does adenosine prevent myocardial micronecrosis following percutaneous coronary intervention? The ADELINE pilot trial. Heart 2002; 88: 293-5. (Pubitemid 34913518)
12. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous intervention on frequency of periprocedural myocardial injury. Am J Cardiol 2004; 94: 1363-6.
13. Herrmann J, Lerman A, Baumgart D, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002; 106: 2180-3. (Pubitemid 35222209)
14. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110: 674-8. (Pubitemid 39056265)
15. Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J 2004; 25: 1822-8. (Pubitemid 39330233)
16. Mood GR, Bavry AA, Roukoz H, Bhatt DL. Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention. Am J Cardiol 2007; 100: 919-23. (Pubitemid 47368096)
17. Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009; 54: 2157-63.
18. Chang SM, Yazbek N, Lakkis NM. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv 2004; 62: 193-7. (Pubitemid 38788696)
19. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA- ACS randomized trial. J Am Coll Cardiol 2007; 49: 1272-8. (Pubitemid 46467240)
20. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8. (Pubitemid 32259905)
21. Fonarow GC, Wright RS, Spencer FA, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005; 96: 611-6. (Pubitemid 41207298)
22. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Eng J Med 2004; 350: 1495-504.
23. Yun KH, Jeong MH, Oh SK, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2009; 137: 246-51.
24. Kim JS, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv 2010; 3: 332-9.
25. Mensah K, Mocanu MM, Yellon DM. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 2005; 45: 1287-91. (Pubitemid 40523151)
26. Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention. J Am Coll Cardiol 2009; 54: 558-65.
27. Patti G, Cannon CP, Murphy S, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention. A collaborative patient- level meta-analysis of 13 randomized studies. Circulation 2011; 123: 1622-32.
28. Lindsay J, Apple S, Pinnow EE, et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatine. Cathet Cardiovasc Intervent 2003; 59: 338-43. (Pubitemid 36792393)
29. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. JACC 2000; 36: 1542-8.
30. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-64. (Pubitemid 34535335)
31. Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008; 101: 279-85. (Pubitemid 351162953)
32. Patti G, Ricottini E, Nusca A, et al. Short-term, highdose Atorvastatin pretreatment to prevent contrastinduced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty: contrast-induced nephropathy] trial. Am J Cardiol 2011; 108: 1-7.